PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant clinical benefits from PARP inhibitors, calling for the needs to further understanding and developing new strategy when employing...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ting, Lei, Guang, Chen, Xue, Li, He, Zhang, Xiaoye, Wu, Nayiyuan, Zhao, Yu, Zhang, Yilei, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles from the Special Issue on Redox Modulation of Cancer Heterogeneity, Therapeutic Resistance and Immunotherapy Efficacy; Edited by Dr. Anita Hjelmeland
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113041/
https://www.ncbi.nlm.nih.gov/pubmed/33722571
http://dx.doi.org/10.1016/j.redox.2021.101928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113041/
https://www.ncbi.nlm.nih.gov/pubmed/33722571
http://dx.doi.org/10.1016/j.redox.2021.101928

Ejemplares similares